Unlocking Widespread Adoption of CAR-Ts
Imagine a world where patients with AL amyloidosis, multiple myeloma and other blood disorders can access a one-time, transformative treatment right at their doorstep. At ImmixBio, we see a horizon where this is possible.
Based on the groundbreaking cell therapy research in the early 2010s of Dr. Carl June at University of Pennsylvania, Dr. Renier Brentjens formerly of Memorial Sloan Kettering, and others, the first cell therapies were approved in the United States in August and October 2017, Kymriah® and Yescarta® for certain types of blood cancers.
Since then, the United States has seen a blossoming of experts in the field, manufacturing sites, as well as clinical and patient experience in the cell therapy space. Despite this progress, due to neurotoxicity and other side effects, 95% of U.S. medical centers are unable to dose these pioneering CAR-T cell therapies. Additionally, also due to neurotoxicity and other side effects, only a narrow band of patients in specific indications are able to benefit from CAR-Ts.
At ImmixBio, we aim to change that paradigm by being the first company to overcome the greatest obstacle to CAR-T adoption: neurotoxicity. By overcoming neurotoxicity, we aim to expand into indications that were not possible in the past (starting with AL Amyloidosis), and places not possible in the past (the 95% of U.S. medical centers today that are unable to dose CAR-T therapies).
Our strategy is to:
- Build on proliferation of cell therapy expertise across the U.S. to deliver FDA approval submissions in AL amyloidosis and multiple myeloma of highly differentiated cell therapy candidates including NXC-201
- Demonstrate the power of overcoming neurotoxicity, divorcing the classical relationship between toxicity and efficacy
- Continue to expand into new indications and advance new cell therapies with similar transformative potential
Our Story
ImmixBio was founded in 2012 by a driven physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent expert and an impact-driven founding family office.
Since then, we have demonstrated a consistent track record of execution yielding over 100 patients treated in clinical trials advancing toward FDA approval submissions in relapsed/refractory AL Amyloidosis, relapsed/refractory multiple myeloma, and relapsed/refractory solid tumors across clinical trials including NEXICART-1 (NCT04720313) for our next-generation CAR-T cell therapy NXC-201, and IMMINENT-01 (NCT05840835) for our tissue specific therapeutic IMX-110 combined with PD-1. Our clinical results have been presented at premier venues including: American Society for Gene and Cell Therapy, International Myeloma Society, and published in Clinical Cancer Research, Haematologica and others.
We are fortunate to report that NXC-201 initial response rates of 95% and 100% have been observed from the Phase 1b/2a NEXICART-1 (NCT04720313) study in patients with multiple myeloma and AL amyloidosis, respectively (as of July 17, 2023). NXC-201 has the potential to be the world’s first out-patient CAR-T and has been awarded Orphan Drug Designation (ODD) by the FDA in both multiple myeloma and AL Amyloidosis. Our lead tissue specific therapeutic IMX-110 is in Phase 1b/2a clinical trials as a monotherapy and IMMINENT-01 (NCT05840835) combination clinical trial with BeiGene’s anti-PD-1 antibody tislelizumab. IMX-110 has been awarded ODD and Rare Pediatric Disease Designation (RPDD) by the FDA.
Accelerated by our team’s unrelenting drive and expertise across cell therapy and other modalities as well as indications, paired with our execution track record, we believe we are uniquely positioned to effect a better future for patient communicates around the globe.
OUR MISSION
Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting!
Leadership
Board Diversity
